The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549 FORM D

## **Notice of Exempt Offering of Securities**

OMB APPROVAL			
OMB Number:	3235-0076		
Estimated average burden			
hours per response:	4.00		

hours per response:

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	None	Entity Type
0000949858	ONCOGENEX F	PHARMACEUTICALS, INC	C. X Corporation
Name of Issuer	SONUS PHARM	IACEUTICALS INC	Limited Partnership
ACHIEVE LIFE SCIENCES, INC.			H
Jurisdiction of Incorporation/Organ	ization		Limited Liability Company
DELAWARE			General Partnership
Year of Incorporation/Organization			Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify	Year)		
Yet to Be Formed			
2. Principal Place of Business an	d Contact Information		
Name of Issuer			
ACHIEVE LIFE SCIENCES, INC.			
Street Address 1		Street Address 2	
1040 West Georgia		Suite 1030	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Vancouver	BRITISH COLUMBIA, CANADA	V6E 4H1	604-210-2217
3. Related Persons			
Last Name	First Name		Middle Name
Bencich	John		
Street Address 1	Street Address 2		
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Su		710/0 110 1
City	State/Province/Count	•	ZIP/PostalCode
Vancouver  Relationship: X Executive Officer	BRITISH COLUMBIA	, CANADA	V6E 4H1
Clarification of Response (if Necess			
Last Name	First Name		Middle Name
Jacobs	Cindy		Middle Name
Street Address 1	Street Address 2		
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Su	ite 1030	
City	State/Province/Count		ZIP/PostalCode
Vancouver	BRITISH COLUMBIA		V6E 4H1
Relationship: X Executive Officer		, -	
Clarification of Response (if Necess	sary):		
Last Name	First Name		Middle Name
Clarke	Anthony		
Street Address 1	Street Address 2		
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Su	ite 1030	
City	State/Province/Count		ZIP/PostalCode
Vancouver	BRITISH COLUMBIA		V6E 4H1
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	sary):		

Last Name	First Name	Middle Name
Xinos	Jaime	
Street Address 1	Street Address 2	
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Suite 1030	
City	State/Province/Country	ZIP/PostalCode
Vancouver	BRITISH COLUMBIA, CANADA	V6E 4H1
Relationship: X Executive Officer Director		
Clarification of Response (if Necessary):		
. , , , , , , , , , , , , , , , , , , ,		
Last Name	First Name	Middle Name
Stewart	Richard	
Street Address 1	Street Address 2	
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Suite 1030	
City	State/Province/Country	ZIP/PostalCode
Vancouver	BRITISH COLUMBIA, CANADA	V6E 4H1
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Martell	Bridget	
Street Address 1	Street Address 2	
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Suite 1030	
City	State/Province/Country	ZIP/PostalCode
Vancouver	BRITISH COLUMBIA, CANADA	V6E 4H1
Relationship: Executive Officer X Director		
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
		Middle Name
Himes Street Address 1	Vaughn Street Address 2	
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Suite 1030	
City	State/Province/Country	ZIP/PostalCode
Vancouver	BRITISH COLUMBIA, CANADA	V6E 4H1
	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Joseph	Donald	
Street Address 1	Street Address 2	
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Suite 1030	
City	State/Province/Country	ZIP/PostalCode
Vancouver	BRITISH COLUMBIA, CANADA	V6E 4H1
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Moyes	Jay	
Street Address 1	Street Address 2	
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Suite 1030	
City	State/Province/Country	ZIP/PostalCode
Vancouver	BRITISH COLUMBIA, CANADA	V6E 4H1
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Mattingly	Martin	
Street Address 1	Street Address 2	
c/o Achieve Life Sciences, Inc.	1040 West Georgia, Suite 1030	
City	State/Province/Country	ZIP/PostalCode

Section 3(c)(6)

Section 3(c)(7)

Section 3(c)(14)

7. Type of Filing	
New Notice Date of First Sale 2022-11-18 First Sale Yet to Occur	r
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to last more than one year?	s X No
9. Type(s) of Securities Offered (select all that apply)	
Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other R	Right to X Other (describe)
Acquire Security	Units consisting of two shares of common stock and one common stock warrant.
10. Business Combination Transaction	
Is this offering being made in connection with a business combination tr or exchange offer?	ransaction, such as a merger, acquisition Yes X No
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside investor \$0 USD	
12. Sales Compensation	
·	D. C. LODDA L. Ela
Recipient	Recipient CRD Number X None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1 City	Street Address 2 State/Province/Country ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US
13. Offering and Sales Amounts	
Total Offering Amount \$25,000,000 USD or Indefinite	
Total Amount Sold \$18,900,000 USD	
Total Remaining to be Sold \$6,100,000 USD or Indefinite	
Clarification of Response (if Necessary):	
14. Investors	
	ons who do not qualify as accredited investors, and enter the number of
such non-accredited investors who already have invested in the offer	
Regardless of whether securities in the offering have been or may b total number of investors who already have invested in the offering:	e sold to persons who do not qualify as accredited investors, enter the
15. Sales Commissions & Finder's Fees Expenses	
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditure is not known, provide an estimate and
Sales Commissions \$0 USD Estimate	
Finders' Fees \$945,000 USD Estimate	
Clarification of Response (if Necessary):	
16. Use of Proceeds	
	or is proposed to be used for payments to any of the persons required to be named as f the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD ☐ Estimate	

Clarification of Response (if Necessary):

## Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

## **Terms of Submission**

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the
  accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
ACHIEVE LIFE SCIENCES, INC.	/s/ John Bencich	John Bencich	Chief Executive Officer	2022-11-28

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.